Proteinase K Market Report 2026

The proteinase k market size has grown rapidly in recent years. It will grow from $5.29 billion in 2025 to $5.86 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to expansion of molecular biology research, growth of academic and clinical laboratories, increasing use of genomic sequencing techniques, rising demand for reliable sample preparation enzymes, availability of standardized enzyme formulations.

The proteinase k market size is expected to see rapid growth in the next few years. It will grow to $8.91 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to increasing investments in precision medicine, rising adoption of advanced diagnostic testing, expansion of biotechnology research pipelines, growing demand for automation-compatible reagents, increasing focus on reproducible research outcomes. Major trends in the forecast period include increasing demand for high-purity enzymes, rising use in dna and rna extraction protocols, growing adoption in molecular diagnostics, expansion of genomics research activities, enhanced focus on sample preparation accuracy.

An increasing prevalence of chronic diseases is expected to drive the growth of the proteinase K market going forward. Chronic diseases are conditions or illnesses that last more than a year and require ongoing medical care. Proteinase K is used in these conditions in preventative or therapeutic applications to extract and isolate DNA (Deoxyribonucleic Acid) and RNA (Ribonucleic Acid) from viruses responsible for various chronic diseases. For example, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older with at least one chronic condition is projected to reach 142.66 million by 2050. Thus, the rising prevalence of chronic diseases is propelling the proteinase K market.

The increasing incidence of infectious diseases, such as tuberculosis, is also expected to boost the growth of the proteinase K market. Tuberculosis (TB) is a bacterial infection caused by Mycobacterium tuberculosis, which primarily affects the lungs but can impact other parts of the body. Proteinase K is used in TB research to extract and isolate DNA and RNA from the Mycobacterium tuberculosis bacterium. For instance, in February 2024, according to GOV.UK, a UK-based government department, tuberculosis cases in England increased by 10.7% in 2023, rising from 4,380 in 2022 to 4,850. Therefore, the growing incidence of infectious diseases such as tuberculosis is driving the proteinase K market.

In January 2023, Lighthouse Pharma, a US-based biopharmaceutical company, acquired the small molecule proteinase inhibitor portfolio from Quince Therapeutics Inc. This acquisition positions Lighthouse Pharma to advance the development of gingipain inhibitors for dementia and other disorders, offering innovative treatment options. Quince Therapeutics Inc., a US-based biotechnology company specializing in proteinase inhibitors, contributes valuable assets to Lighthouse Pharma's research and development efforts.

Major companies operating in the proteinase k market are Merck KGaA, Thermo Fisher Scientific, Qiagen, Roche Holding, Takara Bio, New England Biolabs, Promega Corporation, Bio-Rad Laboratories, Agilent Technologies, Abcam plc, GenScript Biotech, Enzo Life Sciences, PerkinElmer, Bio-Techne, Miltenyi Biotec, Sartorius AG, Lonza Group, FUJIFILM Irvine Scientific, MP Biomedicals, Nacalai Tesque, PanReac AppliChem.

North America was the largest region in the global proteinase K market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global proteinase k market during the forecast period. The regions covered in the proteinase k market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proteinase k market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The proteinase K market consists of sales of acid proteinase, neutral proteinase, and alkaline proteinase. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.